CYTH News and Press, Cyclo Therapeutics Inc. From 09/21/23

Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 ...

2023-08-15 09:35:48 ET Cyclo Therapeutics press release ( NASDAQ: CYTH ): Q2 Net loss for the  $4.6 million. Research and development expenses increased 69% to approximately $3.2 million for the three months ended June 30, 2023, from approximately $1.9 for the three m...

Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end 2023 Company anticipates achieving 60% of enrollment of TransportNPC™ ...

2023-08-03 10:16:24 ET Gainers: Bluejay Diagnostics ( BJDX ) +74% . Adamis Pharmaceuticals ( ADMP ) +59% . T2 Biosystems ( TTOO ) +47% . Community Health Systems ( CYH ) +18% . Cyclo Therapeutics ( CYTH ) +17% . Losers:...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol ® Cyclo™ was detected in the CSF Completers had ...

NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023. “We continue to seek to expand our p...

2023-06-13 13:24:48 ET Gainers: First Wave BioPharma ( FWBI ) +122% . Ideanomics ( IDEX ) +55% . Cohen & Company ( COHN ) +30% . OneConnect Financial Technology ( OCFT ) +27% . Cyclo Therapeutics ( CYTH ) +26% . Acumen Ph...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

2023-06-05 09:24:20 ET Clinical stage biotechnology company, Cyclo Therapeutics ( NASDAQ: CYTH ) enters into an agreement with Rafael ( NYSE: RFL ) to purchase 4M shares and warrants for an aggregate purchase price of $5M. The warrants will have an exercise price o...